BNGO · Insider Trading
Bionano Genomics, Inc. Common Stock
Every open-market purchase and sale reported by BNGO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Albert Luderer | Interim Chief Executive | Buy | +4,000 | +$4.84K |
| 2026-08-21 | Albert Luderer | Interim Chief Executive | Buy | +4,000 | +$4.86K |
| 2026-08-05 | Jonathan V. Dixon | General Counsel | A | +15,000 deriv. | — |
| 2026-08-05 | Mark Oldakowski | Chief Operating Officer | A | +15,000 deriv. | — |
| 2026-08-05 | Alex Reid Hastie | Chief Scientific Officer | A | +54,000 deriv. | — |
| 2026-08-05 | Mark Adamchak | Principal Accounting Officer | A | +5,000 deriv. | — |
| 2026-06-03 | Mark Oldakowski | CHIEF OPERATING OFFICER | F | −27 | −$35 |
| 2026-06-03 | Mark Adamchak | Principal Accounting Officer | F | −7 | −$9 |
| 2026-06-03 | Jonathan V. Dixon | GENERAL COUNSEL | F | −24 | −$31 |
| 2026-06-03 | Alka Chaubey | CHIEF MEDICAL OFFICER | F | −24 | −$31 |
| 2026-05-14 | Aleksandar Rajkovic | Director | A | +9,149 deriv. | — |
| 2026-05-14 | Christopher J Twomey | Director | A | +9,149 deriv. | — |
| 2026-05-14 | Kristiina MD Vuori | Director | A | +9,149 deriv. | — |
| 2026-05-14 | David L Barker | Director | A | +9,149 deriv. | — |
| 2026-05-14 | Yvonne Linney | Director | A | +9,149 deriv. | — |
| 2026-02-18 | Mark Adamchak | Principal Accounting Officer | F | −3 | −$3 |
| 2026-02-18 | Jonathan V. Dixon | GENERAL COUNSEL | F | −6 | −$7 |
| 2026-02-18 | Alka Chaubey | CHIEF MEDICAL OFFICER | F | −18 | −$20 |
| 2026-02-18 | R. Erik Holmlin | PRESIDENT AND CEO | F | −51 | −$56 |
| 2026-02-18 | Mark Oldakowski | CHIEF OPERATING OFFICER | F | −20 | −$22 |
| 2026-02-04 | Mark Adamchak | Principal Accounting Officer | A | +10,890 deriv. | — |
| 2026-02-04 | Alka Chaubey | CHIEF MEDICAL OFFICER | A | +27,737 deriv. | — |
| 2026-02-04 | Jonathan V. Dixon | GENERAL COUNSEL | A | +26,117 deriv. | — |
| 2026-02-04 | R. Erik Holmlin | PRESIDENT AND CEO | A | +69,484 deriv. | — |
| 2026-02-04 | Mark Oldakowski | CHIEF OPERATING OFFICER | A | +27,737 deriv. | — |
| 2025-09-12 | Alka Chaubey | Chief Medical Officer | F | −51 | −$207 |
| 2025-09-12 | Mark Oldakowski | Chief Operating Officer | F | −59 | −$240 |
| 2025-09-12 | Mark Oldakowski | Chief Operating Officer | F | −59 | −$240 |
| 2025-06-12 | Hannah Mamuszka | Director | A | +2,775 deriv. | — |
| 2025-06-12 | Kristiina MD Vuori | Director | A | +2,775 deriv. | — |
| 2025-06-12 | David L Barker | Director | A | +2,775 deriv. | — |
| 2025-06-12 | Yvonne Linney | Director | A | +2,775 deriv. | — |
| 2025-06-12 | Albert Luderer | Director | A | +2,775 deriv. | — |
| 2025-06-12 | Christopher J Twomey | Director | A | +2,775 deriv. | — |
| 2025-06-12 | Aleksandar Rajkovic | Director | A | +2,775 deriv. | — |
| 2025-06-03 | Alka Chaubey | Chief Medical Officer | F | −24 | −$89 |
| 2025-06-03 | Mark Oldakowski | Chief Operating Officer | F | −27 | −$100 |
| 2025-06-03 | Mark Adamchak | Principal Accounting Officer | F | −7 | −$26 |
| 2025-06-03 | Jonathan V. Dixon | General Counsel | F | −25 | −$92 |
| 2025-06-03 | R. Erik Holmlin | President and CEO | F | −75 | −$277 |
| 2025-03-18 | Alka Chaubey | Chief Medical Officer | A | +6,966 deriv. | — |
| 2025-03-18 | Jonathan V. Dixon | General Counsel | A | +6,559 deriv. | — |
| 2025-03-18 | Mark Oldakowski | Chief Operating Officer | A | +6,966 deriv. | — |
| 2025-03-18 | Mark Adamchak | Principal Accounting Officer | A | +3,029 deriv. | — |
| 2025-03-18 | R. Erik Holmlin | President and CEO | F | −198 | −$687 |
| 2025-02-19 | Jonathan V. Dixon | General Counsel | F | −6 | −$34 |
| 2025-02-19 | Alka Chaubey | Chief Medical Officer | F | −18 | −$103 |
| 2025-02-19 | Mark Adamchak | Principal Accounting Officer | F | −4 | −$23 |
| 2025-02-19 | Mark Oldakowski | Chief Operating Officer | F | −20 | −$115 |
| 2025-02-19 | R. Erik Holmlin | President and CEO | F | −51 | −$292 |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Albert Luderer | Interim Chief Executive | 8,000 | $10.00K |
| R. Erik Holmlin | PRESIDENT AND CEO | 1,665 | $2.08K |
| Mark Oldakowski | Chief Operating Officer | 868 | $1.08K |
| Alka Chaubey | CHIEF MEDICAL OFFICER | 620 | $775 |
| Mark Adamchak | Principal Accounting Officer | 253 | $316 |
| Jonathan V. Dixon | General Counsel | 239 | $299 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BNGO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.